Green Tea and Epigallocatechin Gallate (EGCG) for Cancer Prevention: A Systematic Review and Meta-Analysis
- 1 January 2025
- journal article
- review article
- Published by World Scientific Pub Co Pte Ltd in The American Journal of Chinese Medicine
- Vol. 53 (06) , 1755-1784
Abstract
Previous studies have reported inconsistent effects of green tea and its extract, epigallocatechin gallate (EGCG), on cancer prevention. We aimed to uncover the protective effects of green tea or EGCG against cancer, and to assess the dose–response relationship between cancer risk and green tea consumption by performing a comprehensive meta-analysis of cohort studies. A systematic search of the PubMed, Embase, CENTRAL, AMED, CancerLit, AACR, and CBM databases was conducted from the date of database creation to October 26, 2023, to collect randomized controlled trials (RCTs) and cohort studies on the association between green tea or green tea extract EGCG intake and the risk of cancer occurrence. Meta-analysis was performed using the RevMan 5.4 software and Stata 16 after an independent screening of the literature, extraction of information, and evaluation by two investigators of the risk of bias in included studies. Funnel plots were used to evaluate the publication bias. Dose–response relationships were evaluated using a two-stage restricted cubic spline regression model. The study protocol was registered in PROSPERO (CRD42023484787). The search yielded 2334 papers, and 43, including 7 RCTs and 36 cohort studies, were finally included. The results of the meta-analysis showed that green tea (relative risk [RR]: 0.91, 95% confidence interval [CI]: 0.86–0.96) and EGCG (RR: 0.72, 95% CI: 0.54–0.97) could reduce the risk of cancer to a certain extent compared to controls. It had an especially notable effect in reducing the risk of prostate cancer (RR: 0.43, 95% CI: 0.22–0.83), oral cancer (RR: 0.44, 95% CI: 0.01–0.87), gallbladder cancer (RR: 0.72, 95% CI: 0.51–0.94), and hematological cancers (RR: 0.72, 95% CI: 0.49–0.95), with statistically significant differences. Additionally, the dose–response meta-analysis revealed a significant negative linear correlation between high doses, long-term consumption of green tea, and cancer risk. Green tea or EGCG intake can prevent some cancers. High doses and long-term consumption of green tea could achieve better benefits, providing a basis for the dietary guidelines for green tea in preventing cancer. However, given the heterogeneity of the included studies, our findings still need to be validated by conducting higher-quality studies.Keywords
This publication has 77 references indexed in Scilit:
- Regulation of gene expression by modulating microRNAs through Epigallocatechin-3-gallate in cancerMolecular Biology Reports, 2024
- Efficacy of Epigallocatechin-3-Gallate in Preventing Dermatitis in Patients With Breast Cancer Receiving Postoperative RadiotherapyJAMA Dermatology, 2022
- Epigallocatechin gallate inhibits HeLa cells by modulation of epigenetics and signaling pathways3 Biotech, 2020
- Coffee and green tea consumption and subsequent risk of acute myeloid leukemia and myelodysplastic syndromes in JapanInternational Journal of Cancer, 2017
- Coffee and green tea consumption in relation to brain tumor risk in a Japanese populationInternational Journal of Cancer, 2016
- Plasma tea polyphenol levels and subsequent risk of breast cancer among Japanese women: a nested case–control studyBreast Cancer Research and Treatment, 2010
- Coffee consumption and risk of endometrial cancer: A prospective study in JapanInternational Journal of Cancer, 2008
- Coffee consumption and risk of colorectal cancer in a population‐based prospective cohort of Japanese men and womenInternational Journal of Cancer, 2007
- Preventive effects of drinking green tea on cancer and cardiovascular disease: Epidemiological evidence for multiple targeting preventionBioFactors, 2000
- A prospective study of diet, smoking, and lower urinary tract cancerAnnals of Epidemiology, 1993